A review pooled weight measurements from the end of obesity treatment to a later follow-up [1]. Individual trials in our guide to weight regain after stopping a GLP-1 provide a clearer view of specific follow-up periods. The studies in this pooled analysis differed considerably.
What the pooled figures mean
The review included 17 studies and 3,793 participants in groups that stopped treatment. The pooled estimate of weight regain was 7.20%, with a 95% confidence interval of 5.93% to 8.48% [1]. The percentage describes the change in weight after treatment ended. It does not describe the share of previously lost weight that returned.
Separate estimates were 4.83% for liraglutide, 7.19% for semaglutide and 13.04% for tirzepatide. The groups differed in starting weight, earlier weight loss and time since treatment stopped. Eleven studies were retrospective and only three were randomized. The drug-specific figures are indirect comparisons.
What a randomized withdrawal trial can show
SURMOUNT-4 randomized adults who completed an initial tirzepatide treatment period to continue or switch to placebo [2]. Research on whether a lower dose can maintain weight loss studies a different decision from stopping. Over the next 52 weeks, the placebo group gained 14.0% from its week 36 weight. The group that continued tirzepatide lost another 5.5%. Those figures apply to adults who reached the randomized phase.